Internal link ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor September 23, 2026 at 12:00 PM UTC
Internal link ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 September 09, 2026 at 12:00 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences in September 2026 September 02, 2026 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2026 Operating and Financial Results August 13, 2026 at 11:00 AM UTC
Internal link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement June 25, 2026 at 10:35 AM UTC
Internal link ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform June 25, 2026 at 10:25 AM UTC
Internal link ProQR Announces First Quarter 2026 Operating and Financial Results May 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform May 11, 2026 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 May 04, 2026 at 12:00 PM UTC
Internal link ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors April 30, 2026 at 12:00 PM UTC
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event April 08, 2026 at 08:00 PM UTC
Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board April 08, 2026 at 12:00 PM UTC
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 March 25, 2026 at 12:00 PM UTC
Internal link ProQR Announces Year End 2025 Operating and Financial Results March 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference March 03, 2026 at 09:30 PM UTC
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook January 08, 2026 at 01:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 December 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires December 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 December 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients December 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference November 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018 November 07, 2018 at 12:00 PM UTC